Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENENTECH, BIOCINE GP120 HIV VACCINE PHASE II STUDIES SHOULD CONTINUE BUT PHASE III PREVENTIVE TRIALS SHOULD AWAIT MORE DATA -- NIAID AIDS ADVISORY CMTE.

Executive Summary

Phase II trials of Genentech's and Biocine's gp120 HIV vaccines should continue, but the data do not warrant a progression to large-scale Phase III trials, the National Institute of Allergy & Infectious Diseases AIDS Research Advisory Committee recommended at a June 17 meeting.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel